Astellas/Seagen prepare full US filing of bladder cancer dru...

Astellas and Seagen have the data they need for a full licence for their bladder cancer drug Padcev in the US, based on trial results announced over the weekend.

Astellas doubles down on partnership and buys bioelectronics...

Astellas Pharma is to buy bioelectronic medical devices firm iota Biosciences in a deal worth up to $429m, building on a previous research partnership.

NICE backs NHS use for Astellas' Xospata after rethink

NICE has recommended regular NHS funding for Astellas’ Xospata (gilteritinib) monotherapy for certain adult patients with acute myeloid leukaemia

GSK's kidney disease anaemia drug approved in Japan, taking ...

GlaxoSmithKline’s drug for anaemia caused by chronic kidney disease daprodustat has been approved in Japan, taking on a recently approved rival from Astellas. 

Seattle Genetics says data backs Padcev combo for first-line...

Xtandi takes fight to prostate cancer rivals with survival d...